Long-Term Late Toxicity, Quality of Life, and Emotional Distress in Patients With Nasopharyngeal Carcinoma Treated With Intensity Modulated Radiation Therapy

被引:121
作者
McDowell, Lachlan J. [1 ,2 ]
Rock, Kathy [1 ]
Xu, Wei [3 ]
Chan, Biu [1 ]
Waldron, John [1 ]
Lu, Lin [3 ]
Ezzat, Shereen [4 ]
Pothier, David [5 ]
Bernstein, Lori J. [6 ]
So, Nathaniel [1 ]
Huang, Shao Hui [1 ]
Giuliani, Meredith [1 ]
Hope, Andrew [1 ]
O'Sullivan, Brian [1 ]
Bratman, Scott V. [1 ]
Cho, John [1 ]
Kim, John [1 ]
Jang, Raymond [7 ]
Bayley, Andrew [1 ]
Ringash, Jolie [1 ]
机构
[1] Univ Toronto, Dept Radiat Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[3] Univ Toronto, Dept Biostat, Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Univ Hlth Network, Dept Endocrine Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[5] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto Gen Hosp, Toronto, ON, Canada
[6] Univ Toronto, Dept Support Care, Princess Margaret Canc Ctr, Toronto, ON, Canada
[7] Univ Toronto, Div Med Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 02期
关键词
SENSORINEURAL HEARING-LOSS; CANCER-PATIENTS; RADIOTHERAPY TECHNIQUES; FUNCTIONAL ASSESSMENT; PERFORMANCE STATUS; RANDOMIZED-TRIAL; HEAD; NECK; HEALTH; CHEMORADIOTHERAPY;
D O I
10.1016/j.ijrobp.2018.05.060
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To report long-term (> 4 years) toxicity and quality of life (QoL) among patients with nasopharyngeal carcinoma (NPC) treated with intensity modulated radiation therapy (IMRT) in a nonendemic center. Methods and Materials: A cross-sectional cohort study enrolled patients with NPC who were disease-free and >= 4 years after IMRT +/- chemotherapy. Physician-reported adverse events (Common Terminology Criteria for Adverse Events, version 4.03) and patient-reported QoL (Functional Assessment of Cancer Therapy-Head and Neck, Functional Assessment of Chronic Illness Therapy-Fatigue), utilities (Euro-QOL-5D), head and neck symptoms (MD Anderson Symptom Inventory-Head and Neck), and emotional distress (Hospital Anxiety and Depression Scale) were collected. Consenting patients also underwent endocrine screening and audiometry. Results: Among 107 patients enrolled, median age at enrollment and time since treatment were 57 (32-81) and 7.5 years (4.2-11.1), respectively. Most patients (99%) received 70 Gy in 35 fractions; the majority (93%) received concurrent chemotherapy. Mean scores for the Functional Assessment of Cancer Therapy-Head and Neck, Functional Assessment of Chronic Illness Therapy-Fatigue, and EuroQOL-5D were 105.0 (46-148), 116.6 (44-160), and 0.85 (0.29-1.00), respectively. Dry mouth, mucus, swallowing/chewing, memory, and teeth/gum problems were scored highest on the MD Anderson Symptom Inventory-Head and Neck; mean symptom severity and symptom interference scores were 2.3 and 2.4, respectively. Grade 3 or higher physician-reported adverse events were noted in 50 patients (47%), most frequently hearing problems (46, 43%). Audiometry revealed significant bilateral hearing loss (grade >= 3) in 68 patients (72%). Depression (25%), anxiety (37%), and fatigue (28%) were common and strongly correlated with QoL. Most patients (69%) developed hypothyroidism; 1 patient (1%) developed pituitary dysfunction requiring hormone replacement. V50 > 90 and V45 > 99 to the thyroid correlated with significantly higher rates of hypothyroidism. Conclusions: Despite the implementation of IMRT, survivors of NPC still experience many physical symptoms that affect long-term QoL many years after treatment. Depression, anxiety, and fatigue remain common in long-term survivors and are highly correlated with QoL. Crown Copyright (C) 2018 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:340 / 352
页数:13
相关论文
共 54 条
  • [1] Prevalence of hearing loss and differences by demographic characteristics among US adults - Data from the National Health and Nutrition Examination Survey, 1999-2004
    Agrawal, Yuri
    Platz, Elizabeth A.
    Niparko, John K.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (14) : 1522 - 1530
  • [2] Pituitary dysfunction in adult patients after cranial irradiation for head and nasopharyngeal tumours
    Appelman-Dijkstra, Natasha M.
    Malgo, Frank
    Neelis, Karen J.
    Coremans, Ida
    Biermasz, Nienke R.
    Pereira, Alberto M.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 113 (01) : 102 - 107
  • [3] Sensorineural hearing loss following induction chemotherapy plus concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma
    Atchariyasathian, V.
    Pruegsanusak, K.
    Wongsriwattanakul, S.
    [J]. JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2015, 129 (08) : 767 - 772
  • [4] Hypopituitarism after radiotherapy for extracranial head and neck cancers
    Bhandare, Niranjan
    Kennedy, Laurence
    Malyapa, Robert S.
    Morris, Christopher G.
    Mendenhall, William M.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (09): : 1182 - 1192
  • [5] Assessment of quality of life of nasopharyngeal carcinoma patients with EORTC QLQ-C30 and H&N-35 modules
    Cengiz, M
    Özyar, E
    Esassolak, M
    Altun, M
    Akmansu, M
    Sen, M
    Uzel, Ö
    Yavuz, A
    Dalmaz, G
    Uzal, C
    Hiçsönmez, A
    Sarihan, S
    Kaplan, B
    Atasoy, BM
    Ulutin, C
    Abacioglu, U
    Demiral, AN
    Hayran, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (05): : 1347 - 1353
  • [6] SENSORINEURAL HEARING LOSS AFTER TREATMENT OF NASOPHARYNGEAL CARCINOMA: A LONGITUDINAL ANALYSIS
    Chan, S. H.
    Ng, W. T.
    Kam, K. L.
    Lee, Michael C. H.
    Choi, C. W.
    Yau, T. K.
    Lee, Anne W. M.
    Chow, S. K.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (05): : 1335 - 1342
  • [7] Nasopharyngeal carcinoma
    Chua, Melvin L. K.
    Wee, Joseph T. S.
    Hui, Edwin P.
    Chan, Anthony T. C.
    [J]. LANCET, 2016, 387 (10022) : 1012 - 1024
  • [8] Cleeland CS, 2010, MD ANDERSON SYMPTOM
  • [9] Corry June, 2004, Australas Radiol, V48, P170, DOI 10.1111/j.1440-1673.2004.01293.x
  • [10] Edge S.B., 2010, AJCC cancer staging manual, V649